Cargando…
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
BACKGROUND: The current cancer research strongly focuses on immune therapies, where the PD-1, with its ligands plays an important role. It is known that PD-L1 is frequently up-regulated in a number of different cancers and the relevance of this pathway has been extensively studied and therapeutic ap...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641167/ https://www.ncbi.nlm.nih.gov/pubmed/29069824 http://dx.doi.org/10.18632/oncotarget.20346 |
_version_ | 1783271175258898432 |
---|---|
author | Schott, Dorothea Sonja Pizon, Monika Pachmann, Ulrich Pachmann, Katharina |
author_facet | Schott, Dorothea Sonja Pizon, Monika Pachmann, Ulrich Pachmann, Katharina |
author_sort | Schott, Dorothea Sonja |
collection | PubMed |
description | BACKGROUND: The current cancer research strongly focuses on immune therapies, where the PD-1, with its ligands plays an important role. It is known that PD-L1 is frequently up-regulated in a number of different cancers and the relevance of this pathway has been extensively studied and therapeutic approaches targeting PD-1 and PD-L1 have been developed. We used a non-invasive, real-time biopsy for determining PD-L1 and PD-L2 expression in CETCs of solid cancer patients. METHODS: CETCs were determined from blood of 128 patients suffering from breast (72), prostate (27), colorectal (18) and lung (11) cancer. The number of vital CETCs and the expression of PD-L1 and PD-L2 were investigated using the maintrac(®) method. RESULTS: PD-L1 expressing CETCs were detected in 94.5% of breast, 100% of prostate, 95.4% of colorectal and 82% of lung cancer patients whereas only 75% of breast cancer patients had PD-L2 positive CETCs. In the PD-L1 and PD-L2 expressing patients the cell fraction of PD-L1 positive CETCs is significantly higher than the fraction of PD-L2 positive CETCs (54.6% vs. 28.7%; p<0.001). Breast cancer patients with metastatic disease had significantly more PD-L1 positive CETCs as compared to patients without metastasis (median 75% vs. 61.1%; p<0.05). CONCLUSION: PD-L1 seems to be a major factor in immune evasion and is highly expressed on CETCs regardless of the type of cancer. Monitoring the frequency of PD-L1 positive CETCs could reflect individual patient's response for an anti-PD-1/PD-L1 therapy and may be a promising target of anticancer treatment. |
format | Online Article Text |
id | pubmed-5641167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56411672017-10-24 Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors Schott, Dorothea Sonja Pizon, Monika Pachmann, Ulrich Pachmann, Katharina Oncotarget Research Paper BACKGROUND: The current cancer research strongly focuses on immune therapies, where the PD-1, with its ligands plays an important role. It is known that PD-L1 is frequently up-regulated in a number of different cancers and the relevance of this pathway has been extensively studied and therapeutic approaches targeting PD-1 and PD-L1 have been developed. We used a non-invasive, real-time biopsy for determining PD-L1 and PD-L2 expression in CETCs of solid cancer patients. METHODS: CETCs were determined from blood of 128 patients suffering from breast (72), prostate (27), colorectal (18) and lung (11) cancer. The number of vital CETCs and the expression of PD-L1 and PD-L2 were investigated using the maintrac(®) method. RESULTS: PD-L1 expressing CETCs were detected in 94.5% of breast, 100% of prostate, 95.4% of colorectal and 82% of lung cancer patients whereas only 75% of breast cancer patients had PD-L2 positive CETCs. In the PD-L1 and PD-L2 expressing patients the cell fraction of PD-L1 positive CETCs is significantly higher than the fraction of PD-L2 positive CETCs (54.6% vs. 28.7%; p<0.001). Breast cancer patients with metastatic disease had significantly more PD-L1 positive CETCs as compared to patients without metastasis (median 75% vs. 61.1%; p<0.05). CONCLUSION: PD-L1 seems to be a major factor in immune evasion and is highly expressed on CETCs regardless of the type of cancer. Monitoring the frequency of PD-L1 positive CETCs could reflect individual patient's response for an anti-PD-1/PD-L1 therapy and may be a promising target of anticancer treatment. Impact Journals LLC 2017-08-18 /pmc/articles/PMC5641167/ /pubmed/29069824 http://dx.doi.org/10.18632/oncotarget.20346 Text en Copyright: © 2017 Schott et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Schott, Dorothea Sonja Pizon, Monika Pachmann, Ulrich Pachmann, Katharina Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors |
title | Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors |
title_full | Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors |
title_fullStr | Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors |
title_full_unstemmed | Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors |
title_short | Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors |
title_sort | sensitive detection of pd-l1 expression on circulating epithelial tumor cells (cetcs) could be a potential biomarker to select patients for treatment with pd-1/pd-l1 inhibitors in early and metastatic solid tumors |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641167/ https://www.ncbi.nlm.nih.gov/pubmed/29069824 http://dx.doi.org/10.18632/oncotarget.20346 |
work_keys_str_mv | AT schottdorotheasonja sensitivedetectionofpdl1expressiononcirculatingepithelialtumorcellscetcscouldbeapotentialbiomarkertoselectpatientsfortreatmentwithpd1pdl1inhibitorsinearlyandmetastaticsolidtumors AT pizonmonika sensitivedetectionofpdl1expressiononcirculatingepithelialtumorcellscetcscouldbeapotentialbiomarkertoselectpatientsfortreatmentwithpd1pdl1inhibitorsinearlyandmetastaticsolidtumors AT pachmannulrich sensitivedetectionofpdl1expressiononcirculatingepithelialtumorcellscetcscouldbeapotentialbiomarkertoselectpatientsfortreatmentwithpd1pdl1inhibitorsinearlyandmetastaticsolidtumors AT pachmannkatharina sensitivedetectionofpdl1expressiononcirculatingepithelialtumorcellscetcscouldbeapotentialbiomarkertoselectpatientsfortreatmentwithpd1pdl1inhibitorsinearlyandmetastaticsolidtumors |